Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.73 USD
+0.01 (1.78%)
Updated May 14, 2024 04:00 PM ET
After-Market: $0.73 0.00 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Gossamer Bio (GOSS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.39 | $15.00 | $0.50 | 787.50% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Gossamer Bio comes to $6.39. The forecasts range from a low of $0.50 to a high of $15.00. The average price target represents an increase of 787.5% from the last closing price of $0.72.
Analyst Price Targets (7 )
Broker Rating
Gossamer Bio currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
5/6/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/5/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
3/13/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
1/16/2024 | Guggenheim Securities | Vamil Divan | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 9 |
Average Target Price | $6.39 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 92 of 252 |
Current Quarter EPS Est: | 0.34 |